Traws Pharma, Inc.
TRAW
$0.54
-$0.01-2.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 2.73M | 2.79M | 2.85M | 2.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 2.73M | 2.79M | 2.85M | 2.90M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 2.73M | 2.79M | 2.85M | 2.90M |
| SG&A Expenses | 9.59M | 7.80M | 8.52M | 9.67M | 11.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.41M | -- | -- | -- | -- |
| Total Operating Expenses | 21.54M | 22.35M | 20.67M | 18.63M | 23.17M |
| Operating Income | -21.54M | -19.62M | -17.88M | -15.79M | -20.27M |
| Income Before Tax | -21.57M | -19.43M | 9.17M | -13.31M | -17.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.57 | -19.43 | 9.17 | -13.31 | -17.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.57M | -19.43M | 9.17M | -13.31M | -17.82M |
| EBIT | -21.54M | -19.62M | -17.88M | -15.79M | -20.27M |
| EBITDA | -21.40M | -19.51M | -17.81M | -15.77M | -20.26M |
| EPS Basic | -1.62 | -1.56 | 1.14 | -5.24 | -6.39 |
| Normalized Basic EPS | -1.32 | -1.29 | 1.05 | -4.52 | -9.75 |
| EPS Diluted | -1.62 | -1.57 | 1.06 | -5.32 | -6.47 |
| Normalized Diluted EPS | -1.32 | -1.29 | 0.99 | -4.59 | -9.82 |
| Average Basic Shares Outstanding | 44.68M | 34.64M | 30.96M | 24.69M | 16.83M |
| Average Diluted Shares Outstanding | 44.68M | 34.64M | 31.21M | 24.93M | 17.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |